Cubist Pharmaceuticals Company Profile (NASDAQ:CBST)

About Cubist Pharmaceuticals

Cubist Pharmaceuticals logoCubist Pharmaceuticals, Inc. (Cubist) is a biopharmaceutical company focused on the research, development and commercialization of therapies to treat serious medical conditions in acutely ill patients who are hospitalized or are being treated in other acute care settings. As of December 31, 2011, the Company had two marketed products, CUBICIN (daptomycin for injection) and ENTEREG (alvimopan). The Company also co-promotes DIFICIDTM in the United States, under its co-promotion agreement with Optimer Pharmaceuticals, Inc. (Optimer). In September 2013, the Company announced that it has completed the acquisition of Trius Therapeutics Inc. In October 2013, the Company announced that it has completed its acquisition of Optimer Pharmaceuticals, Inc.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: CBST
  • CUSIP: 22967810
Key Metrics:
  • Previous Close: $0.00
  • 50 Day Moving Average: $101
  • 200 Day Moving Average: $78
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 52.55
  • P/E Growth: 0
  • Market Cap: $N/A
Additional Links:
Companies Related to Cubist Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Cubist Pharmaceuticals (NASDAQ:CBST) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Cubist Pharmaceuticals (NASDAQ:CBST)
No equities research coverage for this company has been tracked by


Earnings History for Cubist Pharmaceuticals (NASDAQ:CBST)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/21/2014Q314$0.04$0.58$305.50 million$309.20 millionViewListenView Earnings Details
7/22/2014Q214$0.01$0.23$299.60 million$294.40 millionViewN/AView Earnings Details
4/22/2014Q114$0.33$0.30$285.24 million$261.20 millionViewN/AView Earnings Details
1/22/2014Q413($0.01)$0.29$285.47 million$299.70 millionViewN/AView Earnings Details
10/17/2013Q313$0.34$0.41$267.96 million$266.00 millionViewN/AView Earnings Details
7/18/2013Q2 2013$0.55$0.42$254.93 million$258.80 millionViewN/AView Earnings Details
4/18/2013Q1 2013$0.50$0.34$243.55 million$229.90 millionViewN/AView Earnings Details
1/23/2013Q4 2012$0.48$0.51$246.42 million$245.90 millionViewN/AView Earnings Details
10/18/2012$0.47$0.55ViewN/AView Earnings Details
7/19/2012$0.45$0.68ViewN/AView Earnings Details
4/18/2012$0.63$0.82ViewN/AView Earnings Details
1/19/2012$0.31$0.11ViewN/AView Earnings Details
10/19/2011$0.26$0.33ViewN/AView Earnings Details
7/14/2011$0.43($0.34)ViewN/AView Earnings Details
4/14/2011$0.26$0.34ViewN/AView Earnings Details
1/20/2011$0.34$0.24ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Cubist Pharmaceuticals (NASDAQ:CBST)
Current Year EPS Consensus Estimate: $1.14 EPS
Next Year EPS Consensus Estimate: $1.94 EPS


Dividend History for Cubist Pharmaceuticals (NASDAQ:CBST)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Cubist Pharmaceuticals (NASDAQ:CBST)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/1/2014Steven C GilmanEVPSell48,125$65.39$3,146,893.75View SEC Filing  
8/19/2014Gregory SteaSVPSell38,326$65.88$2,524,916.88View SEC Filing  
8/18/2014Nancy J HutsonDirectorSell9,000$65.00$585,000.00View SEC Filing  
8/18/2014Robert J PerezCOOSell1,003$63.68$63,871.04View SEC Filing  
7/28/2014Steven C GilmanEVPSell40,625$61.57$2,501,281.25View SEC Filing  
5/15/2014Michael BonneyCEOSell3,036$67.50$204,930.00View SEC Filing  
5/15/2014Robert PerezCOOSell1,518$67.50$102,465.00View SEC Filing  
5/15/2014Steven GilmanEVPSell16,340$67.82$1,108,178.80View SEC Filing  
5/14/2014Michael BonneyCEOSell3,840$69.00$264,960.00View SEC Filing  
5/14/2014Robert PerezCOOSell2,400$69.00$165,600.00View SEC Filing  
5/14/2014Steven GilmanEVPSell1,680$69.00$115,920.00View SEC Filing  
3/6/2014Gregory SteaSVPSell19,889$79.74$1,585,948.86View SEC Filing  
2/27/2014Mark CorriganDirectorSell5,000$80.00$400,000.00View SEC Filing  
2/27/2014Michael BonneyCEOSell100,000$81.25$8,125,000.00View SEC Filing  
2/27/2014Robert PerezCOOSell30,000$80.18$2,405,400.00View SEC Filing  
2/20/2014Michael BonneyCEOSell3,112$75.60$235,267.20View SEC Filing  
2/3/2014Kenneth BateDirectorSell6,250$72.15$450,937.50View SEC Filing  
1/15/2014Gregory SteaSVPSell5,312$74.90$397,868.80View SEC Filing  
1/15/2014Robert PerezCOOSell10,000$74.95$749,500.00View SEC Filing  
1/13/2014Robert PerezCOOSell10,000$72.95$729,500.00View SEC Filing  
1/9/2014Kenneth BateDirectorSell10,000$70.00$700,000.00View SEC Filing  
1/2/2014Steven GilmanEVPSell25,000$67.82$1,695,500.00View SEC Filing  
12/2/2013Kenneth BateDirectorSell12,500$67.63$845,375.00View SEC Filing  
9/9/2013Martin RosenbergDirectorSell15,472$65.00$1,005,680.00View SEC Filing  
8/16/2013Robert PerezCOOSell1,024$60.55$62,003.20View SEC Filing  
7/31/2013Gregory SteaSVPSell33,750$61.29$2,068,537.50View SEC Filing  
7/26/2013Nancy J HutsonDirectorSell5,000$53.87$269,350.00View SEC Filing  
7/19/2013Gregory SteaSVPSell4,375$55.00$240,625.00View SEC Filing  
6/3/2013Kenneth BateDirectorSell2,500$54.95$137,375.00View SEC Filing  
6/3/2013Steven C GilmanEVPSell15,125$54.49$824,161.25View SEC Filing  
5/24/2013Mark CorriganDirectorSell14,000$54.60$764,400.00View SEC Filing  
5/22/2013J Matthew SingletonDirectorSell27,500$55.48$1,525,700.00View SEC Filing  
5/20/2013Charles Anthony LaranjeiraSVPSell14,000$51.43$720,020.00View SEC Filing  
5/20/2013Michael W BonneyCEOSell60,000$50.00$3,000,000.00View SEC Filing  
5/20/2013Robert J PerezCOOSell15,000$49.98$749,700.00View SEC Filing  
5/16/2013Michael W BonneyCEOSell2,400$47.88$114,912.00View SEC Filing  
5/16/2013Robert J PerezCOOSell1,500$47.88$71,820.00View SEC Filing  
5/16/2013Steven C GilmanEVPSell1,201$48.88$58,704.88View SEC Filing  
5/15/2013Kenneth BateDirectorSell2,500$48.41$121,025.00View SEC Filing  
5/15/2013Michael W BonneyCEOSell2,979$48.41$144,213.39View SEC Filing  
5/15/2013Robert J PerezCOOSell1,490$48.41$72,130.90View SEC Filing  
5/15/2013Steven C GilmanEVPSell1,017$48.41$49,232.97View SEC Filing  
5/14/2013Michael W BonneyCEOSell3,753$49.18$184,572.54View SEC Filing  
5/14/2013Robert J PerezCOOSell2,346$49.18$115,376.28View SEC Filing  
5/14/2013Steven C GilmanEVPSell1,135$49.18$55,819.30View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Cubist Pharmaceuticals (NASDAQ:CBST)
News IconEPIRUS Biopharma to Slash 40% of Workforce and Replaces CEO - PharmaLive (press release) (subscription) (NASDAQ:CBST) - May 10 at 7:50 PM logoSuperbugs Turn Big Pharma, Gov't Focus To Antibiotics (NASDAQ:CBST) - April 9 at 4:06 PM logoMario Gabelli's Top 5 Stock Picks (NASDAQ:CBST) - March 31 at 3:50 AM logoFarallon Capital Starts New Position in Cubist Pharmaceuticals (NASDAQ:CBST) - March 20 at 4:06 PM logoElliott Management exits position in Covidien (NASDAQ:CBST) - March 4 at 6:05 PM logoElliott Management starts new position in Cubist Pharmaceuticals (NASDAQ:CBST) - March 2 at 6:05 PM logoPrem Watsa's Stock Buys and Sells of Q4 (NASDAQ:CBST) - February 17 at 12:08 AM logoDana Holding Set to Join the S&P MidCap 400 (NASDAQ:CBST) - January 20 at 5:45 PM logoCubist Announces Withdrawal of Listing of CVRs (CBSTZ) from NASDAQ Global Select Market (NASDAQ:CBST) - January 13 at 8:26 AM logoFDA approves Cubists' drug for antibiotic-resistant bacteria (NASDAQ:CBST) - December 19 at 6:07 PM logoCubist sales force seen as potential boon for Merck intestinal drug (NASDAQ:CBST) - December 10 at 8:50 AM logoMerck says still plans to buy Cubist, despite patent setback (NASDAQ:CBST) - December 9 at 6:13 PM logoMerck committed to Cubist after patent losses (NASDAQ:CBST) - December 9 at 10:27 AM logoMerck says still plans Cubist purchase, despite patent setback (NASDAQ:CBST) - December 9 at 8:59 AM logoAfter Big Cubist Buy, Are These 2 Stocks Next to Be Acquired? (NASDAQ:CBST) - December 9 at 8:50 AM logoMerck to take on superbugs with Cubist Pharma buy (NASDAQ:CBST) - December 8 at 6:39 PM logoMerck dives into 'superbug' chase with Cubist (NASDAQ:CBST) - December 8 at 6:30 PM logoMerck to buy Cubist Pharmaceuticals for $8.4 billion (NASDAQ:CBST) - December 8 at 6:09 PM logoCourt rules Hospira can launch generic Cubicin in 2016 (NASDAQ:CBST) - December 8 at 5:39 PM logoUS STOCKS-Wall St falls with energy shares; global data disappoints (NASDAQ:CBST) - December 8 at 1:46 PM logoCubist options unusually active before Merck deal (NASDAQ:CBST) - December 8 at 12:54 PM logoUS STOCKS-Wall St flat after Japan, China data; biotechs climb (NASDAQ:CBST) - December 8 at 11:13 AM logoUS STOCKS-Wall St slips after Japan, China data; energy drags (NASDAQ:CBST) - December 8 at 9:54 AM logoUS STOCKS-Wall St to open lower after Japan, China data (NASDAQ:CBST) - December 8 at 9:10 AM logoMerck, Cubist Agree to $9.5 Billion Acquisition (NASDAQ:CBST) - December 8 at 8:20 AM


What is Cubist Pharmaceuticals' stock symbol?

Cubist Pharmaceuticals trades on the NASDAQ under the ticker symbol "CBST."

How do I buy Cubist Pharmaceuticals stock?

Shares of Cubist Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Cubist Pharmaceuticals stock cost?

One share of Cubist Pharmaceuticals stock can currently be purchased for approximately $101.94.

Cubist Pharmaceuticals (NASDAQ:CBST) Chart for Monday, February, 20, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for Cubist Pharmaceuticals (NASDAQ:CBST)

Earnings History Chart

Earnings by Quarter for Cubist Pharmaceuticals (NASDAQ:CBST)

Dividend History Chart

Dividend Payments by Quarter for Cubist Pharmaceuticals (NASDAQ:CBST)

Last Updated on 2/20/2017 by Staff